NOTOS: A pivotal study of navtemadlin, a first-in-class mouse double minute 2 inhibitor (MDM2i), in patients (pts) with TP53 wild-type (TP53(WT)) Merkel cell carcinoma (MCC) for whom anti PD-1/L1 therapy has failed Meeting Abstract
| Authors: | Wong, M. K. K.; Burgess, M. A.; Chandra, S.; Fecher, L. A.; Gaudy-Marqueste, C.; Silk, A. W.; Hanna, G. J.; Lebbe, C.; Quéreux, G.; Rabinowits, G.; Schadendorf, D.; Dutriaux, C.; Berking, C.; Martin Liberal, J.; Ascierto, P. A.; Houlihan, E.; Steinmann, K.; Chan, T.; Rothbaum, W. P.; Kelly, C. M. |
| Abstract Title: | NOTOS: A pivotal study of navtemadlin, a first-in-class mouse double minute 2 inhibitor (MDM2i), in patients (pts) with TP53 wild-type (TP53(WT)) Merkel cell carcinoma (MCC) for whom anti PD-1/L1 therapy has failed |
| Meeting Title: | 2023 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2023 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-06-01 |
| Language: | English |
| DOI: | 10.1200/JCO.2023.41.16_suppl.TPS9600 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: TPS9600 -- Meeting was also available virtually -- Source: Cinahl |
